Serum interleukin-1 and interleukin-6 are correlated neither with oxidized low density lipoprotein, nor with low-grade inflammation in patients with type 2 diabetes

European Cytokine Network

Volumn 22, Issue 2, 2011, Pages 107-112

  Morteza, Afsaneh ^a   Nakhjavani, Manouchehr ^a   Ghadiri Anari, Akram ^a   Esteghamati, Alireza ^a   Khalilzadeh, Omid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Interleukin 1 ; Interleukin 6; Oxidized low density lipoprotein; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CHRONIC DISEASE; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; SEX DIFFERENCE;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 79960996768     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2011.0282     Document Type: Article

References (46)

1. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol 2009; 20: 363-9.
2. Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol 2010; 610: 403-17.
3. Nakhjavani M, Khalilzadeh O, Khajeali L, et al. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010; 45: 321-7.
4. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008; 70: 193-219.
5. Groeneweg M, Kanters E,Vergouwe MN, et al. Lipopolysaccharideinduced gene expression in murine macrophages is enhanced by prior exposure to oxLDL. J Lipid Res 2006; 47: 2259-67.
6. Bonaterra GA, Hildebrandt W, Bodens A, et al. Increased gene expression of scavenger receptors and proinflammatory markers in peripheral blood mononuclear cells of hyperlipidemic males. J Mol Med 2007; 85: 181-90.
7. Balakrishnan VS, Schmid CH, Jaber BL, Natov SN, King AJ, Pereira BJ. Interleukin-1 receptor antagonist synthesis by peripheral blood mononuclear cells: a novel predictor of morbidity among hemodialysis patients. J Am Soc Nephrol 2000; 11: 2114-21.
8. Signorelli SS, Mazzarino MC, Spandidos DA, Malaponte G. Proinflammatory circulating molecules in peripheral arterial disease. Int J Mol Med 2007; 20: 279-86.
9. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler ThrombVasc Biol 2005; 25: 1213-9.
10. Choi SH, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res 2009; 104: 1355-63.
11. Chavez-Sanchez L, Madrid-Miller A, Chavez-Rueda K, Legorreta- Haquet MV, Tesoro-Cruz E, Blanco-Favela F. Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum Immunol 2010; 71: 737-44.
12. Alexandraki KI, Piperi C, Ziakas PD, et al. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with lowgrade systemic inflammation. J Clin Immunol 2008; 28: 314-21.
13. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation 2000; 102: 191-6.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32 (Suppl. 1): S62-67.
15. Lubrano V, Del Turco S, Nicolini G, Di Cecco P, Basta G. Circulating levels of lectin-like oxidized low-density lipoprotein receptor- 1 are associated with inflammatory markers. Lipids 2008; 43: 945-50.
16. Cesari M, Kritchevsky SB, Nicklas BJ, et al. Lipoprotein peroxidation and mobility limitation: results from the Health, Aging, and Body Composition Study. Arch Intern Med 2005; 165: 2148-54.
17. Lu Q, Bjorkhem I, Wretlind B, Diczfalusy U, Henriksson P, Freyschuss A. Effect of ascorbic acid on microcirculation in patients with Type II diabetes: a randomized placebo-controlled cross-over study. Clin Sci (Lond) 2005; 108: 507-13.
18. Doo YC, Han SJ, Lee JH, et al. Associations among oxidized lowdensity lipoprotein antibody C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris. Am J Cardiol 2004; 93: 554-8.
19. Guldiken B, Guldiken S, Turgut B, et al. The roles of oxidized lowdensity lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke. Angiology 2008; 59: 224-9.
20. Park SH, Kim JY, Lee JH, Park HY. Elevated oxidized lowdensity lipoprotein concentrations in postmenopausal women with the metabolic syndrome. Clin Chim Acta 2011; 412: 435-40.
21. Lapointe A, Couillard C, Piche ME, et al. Circulating oxidized LDL is associated with parameters of the metabolic syndrome in postmenopausal women. Atherosclerosis 2007; 191: 362-8.
22. Derosa G, D'Angelo A, Salvadeo SA, et al. Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. Horm Metab Res 2010; 2: 8-13.
23. Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 2007; 50: 2218-25.
24. Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels Is adipocyte size associated with inflammation in adults? J Endocrinol Invest 2007; 30: 210-4.
25. Bessa SS, Hamdy SM, Ali EM. Haptoglobin gene polymorphism in type 2 diabetic patients with and without nephropathy: An Egyptian study. Eur J Intern Med 2007; 18: 489-95.
26. Akalin A, Alatas O, Colak O. Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients. Eur J Endocrinol 2008; 158: 47-52.
27. Hyun YJ,Koh SJ, Chae JS, et al. Atherogenecity ofLDLand unfavorable adipokine profile in metabolically obese, normal-weightwoman. Obesity (Silver Spring) 2008; 16: 784-9.
28. Saremi A, Anderson RJ, Luo P, et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 2009; 203: 610-4.
29. Vitale C, Gebara O, Mercuro G, et al. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk. Maturitas 2005; 50: 239-46.
30. Rachon D, Mysliwska J, Suchecka-Rachon K, Wieckiewicz J, Mysliwski A. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol 2002; 172: 387-95.
31. Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J 2007; 401: 1-11.
32. Lopes-Virella MF, Virella G. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes 1996; 45(Suppl. 3): S40-44.
33. Goncalves I, Cherfan P, Soderberg I, Nordin Fredrikson G, Jonasson L. Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers. Autoimmunity 2009; 42: 203-8.
34. Guarda G, So A: Regulation of inflammasome activity. Immunology 2010; 130: 329-36.
35. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
36. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. Arch Physiol Biochem 2009; 115: 240-7.
37. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
38. Taneja N, Coy PE, Lee I, Bryson JM, Robey RB. Proinflammatory interleukin-1 cytokines increase mesangial cell hexokinase activity and hexokinase II isoform abundance. Am J Physiol Cell Physiol 2004; 287: C548-557.
39. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006; 57(Suppl. 10): 43-51.
40. Saltevo J, Vanhala M, Kautiainen H, Kumpusalo E, Laakso M. Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population-based study. Diabet Med 2008; 25: 747-50.
41. Ybarra J, Lehmann TN, Golay A, et al. Gender-based dimorphic pattern for interleukin-1 receptor antagonist in type 2 diabetes mellitus. Diabetes Metab 2008; 34: 75-81.
42. Saltevo J, Kautiainen H, Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gend Med 2009; 6: 463-70.
43. Saltevo J, Laakso M, Jokelainen J, et al. Levels of adiponectin Creactive protein and interleukin-1 receptor antagonist are associated with insulin sensitivity: a population-based study. Diabetes Metab Res Rev 2008; 24: 378-83.
44. Nakhjavani M, Morteza A, Meysamie A, et al. Serum heat shock protein 70 and oxidized LDL in patients with type 2 diabetes: does sex matter? Cell Stress Chaperones 2010; 1: 26.
45. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.
46. Dinarello CA. The interleukin-1 family: 10 years of discovery. Faseb J 1994; 8: 1314-25.